Cerebrospinal fluid (CSF) overproduction results from either CSF infection or choroid plexus hypertrophy or tumor, with only a single idiopathic case described so far. We report a unique case of a male infant with Crouzon syndrome who presented with intracranial hypertension, caused by up to 4-fold increase in CSF daily production. Conditions related to CSF overproduction, namely central nervous system infections and choroid plexus hypertrophy or tumor, were ruled out by repeated magnetic resonance imaging and CSF samples. Medical therapy failed to reduce CSF production and the patient underwent several shunting procedures, cranial expansion, and endoscopic coagulation of the choroid plexus. This article thoroughly reviews pertinent literature on CSF production mechanisms and possible therapeutic implications.

Received: October 25, 2013
Accepted: August 10, 2014

Correspondence to:
Paolo Frassanito
Pediatric Neurosurgery
Catholic University Medical School
Largo Agostino Gemelli 8
00168 Rome, Italy
paolo.frassanito@gmail.com
Hydrocephalus is generally defined as abnormal accumulation of cerebrospinal fluid (CSF) within the ventricles and subarachnoid spaces, and is often associated with dilatation of the ventricular system and increased intracranial pressure (ICP). It can be regarded as a disparity between production and absorption of cerebrospinal fluid (CSF), almost always as a result of CSF flow obstruction either at the ventricular level (eg, foramen of Monro, aqueduct of Sylvius, outlets of fourth ventricle) or the subarachnoid level (eg, basal cisterns, arachnoid granulations, or other points of absorption). More rarely hydrocephalus is a result of impaired absorption of CSF, due to increased venous pressure in the dural sinuses or at the jugular veins (1) and even more rarely of choroid plexus hyperplasia (2-4) or choroid plexus tumors (5-7). Furthermore, CSF production may be increased by CSF infections and meningitis (8), along with the concomitant decrease in CSF absorption. Hydrocephalus resulting from excessive production of CSF and not related to the conditions described above has been described in the literature by a single case report in 1989 (9).

We present a unique case of idiopathic CSF overproduction and the specific difficulties arising from its management. This case prompted us to review the literature focusing on the molecular mechanisms of CSF production and the drugs regulating this process.

**CASE REPORT**

A 6-month-old male infant, born to non-consanguineous parents, presented with macrocrania, irritability, and multiple episodes of vomiting. He also had dysmorphic features, in particular low-set ears, hypertelorism with exorbitism, mandibular prognatism with inverted bite, and broad and varus big toes. The clinical diagnosis of Crouzon syndrome was confirmed by a genetic test, showing FGFR2 gene mutation. Head computed tomography (CT) scan showed a premature fusion of the squamosal and parieto-mastoid suture bilaterally with open sutures at the cranial vault (Figure 1). Brain magnetic resonance imaging (MRI) showed a moderate ventriculomegaly with wide pericranial subarachnoid spaces and a small-sized posterior cranial fossa with low insertion of the tentorium without Chiari malformation or crowded appearance of the neural structures. Angio-MR sequences showed a normal venous pattern with a slight predominance of the right transverse sinus. Prolonged monitoring (48 hours) of the ICP via an intraparenchymal sensor showed pathologically high values. Thus, a ventriculoperitoneal shunt (VPS) was placed, with prompt resolution of the preoperative symptoms. Intraoperative CSF samples showed no evidence of infections.

Two months later, the patient started vomiting daily. Pediatric work-up ruled out systemic issues. MRI did not show any VPS malfunction but showed craniofacial disproportions.
tion, with crowded posterior cranial fossa and downward herniation of cerebellar tonsils (Figure 2). A posterior cranial expansion with decompression of the foramen magnum was performed. The postoperative period was complicated by CSF leak at the surgical wound, requiring exteriorization of the shunt. Unexpectedly, the average amount of drained CSF was 1200 mL/d. Patient did not present with any symptom and CT scan ruled out any complication of overdrainage. Repeated CSF samples ruled out any infection. No evidence of choroid plexus hypertrophy or tumor was present on MRI. The CSF production was not reduced by a trial of acetazolamide, but was increased to 1400 mL/d. Additionally, Colton blood group analysis showed a normal expression of Colton antigen, which is found on aquaporin 1 protein.

The subsequent placement of VPS was early complicated by massive ascites. Thus, we placed a ventriculoatrial shunt (VAS) and a concomitant “protective” external ventricular drainage (EVD). Transient closure of EVD, in order to challenge the cardio-vascular system to receive such a daily amount of CSF, was associated to an increased blood level of brain natriuretic peptide (BNP). Finally, two CSF shunt devices were concomitantly placed, namely a VPS on the left side and a VAS on the right side, both utilizing a middle pressure valve.

A few months later, the child suffered again from symptoms of increased intracranial pressure. After surgical revision of both shunting devices, MRI confirmed cranio-cerebral disproportion with slit ventricles. A biparietal cranial expansion was therefore performed. However, postoperative CSF drainage still ranged between 1400 mL and 1700 mL per day, requiring once again dual shunting. After 5 weeks a new shunt malfunction required exteriorization of both CSF shunts, confirming daily overproduction of CSF (about 1500 mL/d). A pharmacological approach with terlipressin administration was attempted with poor results. Thus, in spite of normal appearance of the choroid plexuses at MRI, endoscopic choroid plexus coagulation was performed bilaterally. Due to small ventricular size, the procedure was performed through bilateral occipital access and using neuronavigation (Figure 3). Since the first post-operative day, the CSF drainage rate halved to 700-800 mL/d. In spite of this important reduction of the CSF production rate, it was necessary to perform dual shunting. The postoperative course was uneventful and the patient was doing well at 6-month follow-up.

**DISCUSSION**

Hydrocephalus resulting from CSF overproduction is a rare disease and is usually caused by pathological conditions affecting the choroid plexus, namely hyperplasia or tumor. In the last decade, endoscopic coagulation of the choroid plexus has become a treatment option for this condition, warranting shunt independency, with lower complication rate compared to surgical plexectomy (10). In the case of choroid plexus tumor, the surgical resection of the tumor usually reduces CSF production. Persistent hydrocephalus, requiring the placement of a CSF shunting device, is possibly related to the concomitant impaired absorption of CSF, ascribed to chemical arachnoiditis secondary to the presence of the tumor in the ventricular system (11,12). Similarly, CSF infections and meningitis (8) may increase the CSF production, along with the concomitant decrease in CSF absorption. Antibiotic treatment of the infection usually leads to normalization of CSF production but not necessarily to the treatment of the associated hydrocephalus, since the structures devoted to the CSF absorption may be definitely impaired, thus usually requiring a shunting procedure.
To our knowledge, a single case of idiopathic CSF overproduction, ie, not related to the conditions described above, has been reported in the English-language literature so far (9). In this case from 1989, increased daily production of CSF could have been exacerbated by the infections that the patient had suffered from in the months before the reported CSF output records. Thus, hydrocephalus related to idiopathic CSF overproduction remains a questionable pathological entity.

In our case, there was no evidence of CSF infection in the patient’s clinical history. The patient with Crouzon syndrome suffered from a communicating hydrocephalus secondary to impressive idiopathic CSF overproduction. In patients with Crouzon syndrome, hydrocephalus is present in up to 40% of cases and is usually related to venous outlet obstruction and small posterior cranial fossa (13). In the present case, the initial MRI showed normal dural sinuses anatomy, and the posterior cranial fossa was not particularly small and crowded. Serial MRI performed to investigate the cause of CSF overproduction ruled out concomitant pathological conditions affecting the choroid plexuses. Interestingly, the patient did well over two months after the initial placement of a CSF shunt, so that it is possible that the device placement precipitated CSF overproduction via an unknown mechanism. The absence of underlying conditions causing the CSF overproduction together with the young age of the patient and his comorbidities raised particular issues in the management of this case. The placement of VPS was complicated by massive ascites, with the young age of the patient and his comorbidities led occlusion and small posterior cranial fossa (13). In the present case, the initial MRI showed normal dural sinuses anatomy, and the posterior cranial fossa was not particularly small and crowded. Serial MRI performed to investigate the cause of CSF overproduction ruled out concomitant pathological conditions affecting the choroid plexuses. Interestingly, the patient did well over two months after the initial placement of a CSF shunt, so that it is possible that the device placement precipitated CSF overproduction via an unknown mechanism. The absence of underlying conditions causing the CSF overproduction together with the young age of the patient and his comorbidities raised particular issues in the management of this case. The placement of VPS was complicated by massive ascites, as expected. Although in the previous case report, the 2.5-year-old child with more than four times the expected rate of CSF production was successfully treated with a VAS (9), in the present case the cardiovascular system did not tolerate such a daily amount of CSF, so that we finally placed a VAS on the right side and a VPS on the left side. Cardiac function was thereafter monitored by ultrasound and weekly blood level of BNP in order to promptly rule out any volume overload. Unfortunately, the presence of two CSF shunt devices reinforced the spontaneous tendency of the cranial vault sutures to fuse due to the underlying syndrome condition, thereby leading to the development of secondary craniosynostosis and craniofacial disproportion (14). In spite of surgical expansion of the cranial vault, the ventricles remained particularly small, thus resulting in a constant risk of shunt obstruction.

Finally, the endoscopic coagulation of the choroid plexus, though initially contraindicated due to the risk related to the small size of the ventricular cavities, was performed as a last resort option when the other treatment options failed. This procedure resulted in a significant reduction of CSF production, thus confirming its role in complicated cases of hydrocephalus (15).

This unique case of idiopathic CSF overproduction prompted us to review the mechanisms of CSF production, which are still far from being completely understood, in order to identify possible targets of a medical therapy.

CSF production

CSF production is an active process, which according to the classical theory takes place mainly in the epithelial cells of the choroid plexuses (16-19). The driving force for fluid secretion is an osmotic gradient due to the active and unidirectional flux of ions from one side of the epithelial monolayer to the other (20). The main ions and small molecules secreted by the choroid plexus through transporters and ion channels are Na⁺, Cl⁻, HCO₃⁻, and H₂O, while K⁺ ions are absorbed (21,22) (Table 1).

Moreover, there is active water secretion through transmembrane proteins referred to as aquaporins (AQPs) (39). Among the 13 known mammalian AQPs, five have been identified in the central nervous system (CNS), namely AQPI, AQP4, AQP7, AQP9, and AQP11 (40).

Although the mechanism of ion secretion has been clarified and most of the involved transporters have now been localized to specific membranes (21,22), the role of AQPs in CSF physiology and pathophysiology is still uncertain. AQP1 and 4 are the most expressed subtypes in the mammalian CNS. AQP1 is highly expressed at the apical surface of the choroid plexus epithelium (39,41) whereas AQP4, the most abundant water channel in the brain, is expressed by ependymal cells, glia limitans interna and externa cells, at the perivascular end feet of astrocytes that form the blood-brain barrier, and in the cerebellum, supraoptic and suprachiasmatic nucleus of the hypothalamus, hippocampal dentate gyrus and areas CA-1 and CA-3, neocortex, nucleus of stria terminalis, and medial habenular nucleus (40).

Distribution of AQP1 at the choroid plexus apical surface suggests its role in CSF production. Studies on AQP1 knockout mice showed a decrease in both CSF production and ICP values compared with wild-type mice, although the latter effect could be related to the decrease in the central venous pressure in AQP1 knockouts due to
the effect on the kidneys (42,43). A recent literature search for articles on the role of AQP1 in hydrocephalus found just 5 papers, 3 on animal models and 2 on humans (44). Down-regulation of AQP1 has been reported in animal studies and in a case report on a 15-month-old girl with choroid plexus hyperplasia (45), while a small case series of choroid plexus tumors showed a heterogeneous pattern of AQP1 in papillomas and a weak expression in a single case of choroid plexus carcinoma (46). These data suggest a possible existence of a feedback mechanism on AQP1 expression in response to hydrocephalus (40). In our case, chemical analysis of the CSF showed a normal glucose level, very low protein values (3-5 mg/dL), and absent cells in the patient’s clinical history. These data are consistent with active secretion of water at the ventricular level in spite of very low oncotic pressure of the CSF. Thus, even if no clinical case of hydrocephalus has been related to a pure deficiency of aquaporins, we performed a molecular analysis of Colton antigen expression during blood tests (Colton antigen is found on AQP1), in order to investigate any mutation of AQP1. However, this test did not show significant anomalies.

Studies on AQP4 role in brain edema in knockout mice models showed a protective role of the protein in vasogenic edema development but an active role in cytotoxic edema development (47,48). Animal hydrocephalus models showed an up-regulation of AQP4 expression in the blood-CSF and blood-brain barriers, suggesting the presence of an adaptive feedback mechanism that lowers the production and increases the clearance of CSF in cases when trans-parenchymal flow and hydrocephalic edema are observed (40). Recently, an increase in AQP4 has been reported in the CSF in human congenital hydrocephalus, which could be the result of ependyma denudation and subsequent diffusion of AQP4 from the parenchyma to the CSF (49). Recent data has focused on the role of AQP4, which is mainly distributed in the perivascular spaces, in the regulation of CSF homeostasis (50). Moreover, AQP4 deficit has been shown to cause hydrocephalus in experimental models (50).

In conclusion, the traditional explanation that the CSF is produced by the choroid plexuses and reabsorbed by the arachnoid villi has been questioned. A study in children hypothesized the presence of a minor pathway involving the perivascular spaces as a site of CSF reabsorption (51). The present case of persistent overproduction of CSF after the coagulation of the choroid plexuses further brings into question the origin of the CSF. Recent insights have shifted the attention to the microvessels and their perivascular spaces, as sites responsible of

| Transporter Route of action Site of expression in CP cells References |
|-----------------|---------------------------------------|-----------------|
| Na⁺-K⁺-ATPase Na⁺ secretion Apical membrane (3 isoforms) Zlokovic et al 1993 (23) |
| Na⁺-K⁺-2Cl⁻ cotransporter Still debated, probably absorption of Na⁺, Cl⁻ and K⁺ Apical membrane Wu et al 1998 (24), Angelow et al 2003 (25) |
| K⁺-Cl⁻ cotransporters K⁺ and Cl⁻ secretion KCC3 isoform: Basolateral membrane KCC4 isoform: Apical membrane Pearson et al 2001 (26) |
| Cl⁻-HCO₃⁻ exchange HCO₃⁻ secretion Cl⁻ absorption Basolateral membrane Johanson et al 1990 (27) |
| Na⁺-HCO₃⁻ cotransporters Isomers NBCNa and NBC: Na⁺ and HCO₃⁻ absorption Isomer NBC4g: HCO₃⁻ secretion NBCNa and NBC: Basolateral membrane NBC4g: Apical membrane Praetorius et al 2004 (28), Fukuda et al 2013 (29) |
| AQP1 Probably H₂O secretion Apical membrane Nielsen et al 1993 (30); Boassa et al 2006 (31) |
| AQP4 To be determined Cytoplasmatic organelles membranes Venero et al 1999 (32) |
| Kv channels K⁺ secretion Apical membrane (3 isoforms) Speake et al 2004 (33) |
| Kir channels K⁺ secretion Apical membrane Döring et al 1998 (34); Nakamura et al 1999 (35) |
| Anion channels Inward-rectifying channels and volume-conductance channels: probably HCO₃⁻ and Cl⁻ secretion Not known (theoretical site: Apical membrane) Speake et al 2000 (36) |
| TRP channels TRPV4 and TRPM3: non-selective cation channels that increase transcellular ion flux and paracellular permeability to adjust to changes in extracellular osmolarity Not known Liedtke et al 2000 (37); Jo et al 2013 (38) |
the establishment of homeostasis between CSF and the interstitial fluid, questioning the net CSF production by the choroid plexus (52,53).

**Regulation of CSF production**

Different molecules have been implicated in the regulation of CSF production (Table 2). One of the corticosteroid action mechanisms for reducing brain edema and ICP is the reduction of CSF production mediated by a decreased activity of Na⁺-K⁺-ATPase (54).

Similarly, CSF production may be influenced by anesthetic agents (55). Halothane decreases CSF production by acting on the V1 receptor of vasopressin, with no net change in the blood flow to the choroid plexus (56). Other agents, such as thiopental, midazolam, and etomidate, may decrease CSF production by reducing both cerebral blood flow (CBF) and cerebral metabolic rate for oxygen when used in high doses (57). Although opioid anesthetics, including fentanyl, can increase ICP (58-60) and are generally believed not to influence CSF production (61), high doses of fentanyl have been reported to reduce CSF production in dogs (62). As opposed to this, ketamine increases the CSF production secondary to an increase in CBF (63). Enflurane, despite a reduced CBF, causes an increase in choroid plexus metabolism, resulting in an increased CSF production (64). Moreover it increases the resistance to reabsorption of CSF, which together with increased CSF production, contributes to increasing ICP (56,65).

Interestingly, a widely used substance such as caffeine, in rats showed opposite effects on CSF production: acute caffeine treatment (oral intake) reduced CSF production, while a chronic intake resulted in ventriculomegaly, due to increased CSF production and potentially associated periventricular leukomalacia (66). Such an effect of caffeine is mediated by A₁ adenosine receptor. The increased CSF production is the result of an increased activity of Na⁺-K⁺-ATPase at the choroid plexus level, which establishes a sodium gradient across the choroid epithelial cells, as well as of an elevated CBF (66).

These molecules are not used in neurosurgical practice to regulate the CSF production, but acetazolamide, a carbonic anhydrase inhibitor, has been used for a long time to reduce CSF production in idiopathic intracranial hypertension. In vivo studies after administration of acetazolamide showed a 50% decrease in CSF production despite a 2-fold increase in blood flow to choroid plexus (67). Carbonic anhydrases are a group of enzymes that catalyze the production of HCO₃⁻ and H⁺ from H₂O and CO₂. Although carbonic anhydrases are not directly involved in ion transport, they are believed to have an important role in CSF secretion on the basis of the effects of their inhibitors (21). Unfortunately, acetazolamide is not always effective and its long-term use can be difficult to tolerate by both adults and children. In children, potential side effects are lethargy, poor feeding, tachypnea, diarrhea, and electrolyte imbalances (hyperchloremic metabolic acidosis). Finally, a paradoxical increase in CSF production may be observed after acetazolamide treatment.

**Table 2. Drugs that may influence CSF production at choroid plexus level and their proposed mechanism of action**

| Drug              | Effect on CSF production | Proposed mechanism of action                                      |
|-------------------|--------------------------|------------------------------------------------------------------|
| Corticosteroids   | Reduced                  | Reduced Na⁺-K⁺-ATPase activity                                    |
| Acetazolamide     | Reduced                  | Carbonic anhydrase inhibitor                                     |
|                   |                          | Interactions with AQP1 and AQP4                                  |
| Furosemide        | Reduced                  | Weak carbonic anhydrase inhibitor                                |
| Bumetanide        | Reduced                  | Blocks Na⁺-K⁺-2Cl⁻ cotransporter                                 |
|                   |                          | Inhibitory effect on AQP1 and AQP4                               |
| Vasopressin       | Reduced                  | Choroid plexus arterioles vasoconstriction                       |
| Halotane          | Reduced                  | Interaction with vasopressin V1 receptor                          |
| Thiopental (high doses) | Reduced                | Reduction of CBF and cerebral metabolic rate for oxygen          |
| Midazolam (high doses) | Reduced                | Reduction of CBF and cerebral metabolic rate for oxygen          |
| Etomidate (high doses) | Reduced                | Reduction of CBF and cerebral metabolic rate for oxygen          |
| Fentanyl (high doses) | Reduced                | Not determined                                                   |
| Caffeine          | Acute effect: Reduced   | A₁ adenosine receptor mediated increased Na⁺-K⁺-ATPase activity + |
|                   | Chronic effect: Increased| Increased CBF                                                     |
| Ketamine          | Increased                | Increase in cerebral blood flow                                   |
| Enflurane         | Increased                | Increase in choroid plexus metabolism                             |

*Abbreviations: AQP – aquaporin; CBF – cerebral blood flow.
zolamide administration because of increased levels of circulating CO₂ and subsequent vasodilatation and increased cerebral blood flow, as observed in the present case. Another drug that has a weak carbonic anhydrase inhibition activity is the widely used loop diuretic furosemide, which has also been shown to decrease CSF production (68). Similarly, bumetanide, another loop diuretic, blocks Na⁺-K⁺-2Cl⁻ cotransporter, thus showing a significant reduction (47%) in CSF production in animal models (69). Interestingly, bumetanide also showed an inhibitory effect on AQP1 and AQP4 (70). This finding led to the development of molecules based on bumetanide structure like arylsulphonamide AqB013 as an antagonist for AQP1 and AQP4 (71). It is worth to note that acetazolamide is also part of arylsulphonamide family. Although its potential effects on AQPs are still debated (72), recent studies have shown an interaction with AQP1, both in vitro (73) and in vivo (74), and a possible reversible inhibition of AQP4 (75).

Experimental data showed that circulating antidiuretic hormone (ADH), also known as vasopressin, markedly decreased CSF production in rabbits (76) and sheep (77). This effect is presumably related to choroid plexus arterioles vasoconstriction mediated by vasopressin V₁a receptor, which has been localized on the choroidal tissue by both autoradiography and mRNA analysis (78,79). On the contrary, vasopressin V₁b receptors, which mainly mediate corticotrophin secretion from the pituitary, are less expressed in choroid plexus tissue. However, an increment in V₁b mRNA was documented after salt-loading, suggesting a role in the regulation of brain water content and cerebral edema (80).

The role of endogenous vasopressin in CSF is still debated and is probably related to brain water regulation (80). It may arise from three sources: transport into the CSF from peripheral blood (81,82), central release from hypothalamic neurons (83), and in situ synthesis and release into the CSF from epithelial cells of the choroid plexus (84-86). Vasopressin production by the choroid plexus is increased by beta-adrenergic agonists and vasointestinal peptide, which indicates that the process is under both endocrine and neuronal control (87). Therefore, vasopressin could have an autocrine and paracrine effect, playing a role in the chain of events that enables either hormonal or neuronal influence on the control of CSF production (20). In the present case report, an off-label medical trial with low dosage intravenous terlipressin was started with the parents’ consent. Terlipressin is an analogue of vasopressin, acting on three different receptors: vasopressin receptor V1a, vasopressin receptor V1b, and, less actively, on vasopressin receptor V₂, which controls free water absorption in the renal medulla. Its current clinical use is in septic shock (88), hepatorenal syndrome (89), and esophageal varices bleeding (90). In the present case, this medical therapy had a promising effect of halving the daily amount of drained CSF since the third day of therapy and the child maintained a good clinical status without hemodynamic complications. However, due to the risks related to a prolonged vasoconstrictor therapy, terlipressin was stopped after 6 days with a new increase in the drained CSF volume to pre-therapy levels without chemical or microbiological alterations. Since the administration modality and potential risks of cardiovascular disease and fluid imbalance do not make terlipressin an ideal candidate for long-term therapy, further studies should identify most manageable and selective analogues of vasopressin.

CONCLUSIONS

CSF production is a complex and active process that involves a huge number of transporters, with insufficiently understood regulatory mechanism, which makes the management of idiopathic CSF overproduction a complicated issue. This extremely rare pathological condition could be related to the malfunction of ions or water transporters at ependymal and choroid plexus level or to an imbalance in the CSF production regulatory mechanism. Drug therapy has so far failed to control the CSF production, so that surgical and endoscopic options, in particular choroid plexus coagulation, should be considered. A better understanding of the molecular substrates of the CSF production could lead to the development of targeted drugs that could reduce CSF production and alleviate intracranial hypertension symptoms in hydrocephalic patients and potentially have a role in reducing brain edema related to ischemic and neoplastic lesions.

Funding: None.

Ethical approval: Not required.

Declaration of authorship: GT drafted the manuscript and analyzed and interpreted the data. PF conceived the study, analyzed and interpreted the data, and revised the manuscript. CDR analyzed and interpreted the data, supervised the study, and gave the final approval.

Competing interests: All authors have completed the Unified Competing Interest form at www.cmj.hr/oca_disclosure.pdf (available on request from the corresponding author) and declare no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

References

1. Frassanito P, Massimi L, Tamburrini G, Caldarelli M, Pedicelli
A, Di Rocco C. Occipital sinus pericranii superseding both jugular veins: description of two rare pediatric cases. Neurosurgery. 2013;72:E1054-8. Medline:23407290 doi:10.1227/NEU.0b013e31828baa4b

2 Fujimoto Y, Matsushita H, Plese JR, Marino R Jr. Hydrocephalus due to diffuse villous hyperplasia of the choroid plexus. Case report and review of the literature. Pediatr Neurosurg. 2004;40:32-6. Medline:15007227 doi:10.1159/000076575

3 Iplikcioglu AC, Bek S, Gökçüman CA, Bikmaz K, Cosar M. Diffuse villous hyperplasia of choroid plexus. Acta Neurochir (Wien). 2006;148:691-4. Medline:16523225 doi:10.1007/s00701-006-0753-1

4 Cataltepe O, Liptzin D, Jolley L, Smith TW. Diffuse villous hyperplasia of the choroid plexus and its surgical management. J Neurosurg Pediatr. 2010;5:518-22. Medline:20433267 doi:10.3171/2009.12.PEDS0960

5 Eisenberg HM, McComb JG, Lorenzo AV. Cerebrospinal fluid overproduction and hydrocephalus associated with choroid plexus papilloma. J Neurosurg. 1974;40:381-5. Medline:4544345 doi:10.3171/jns.1974.40.3.0381

6 Milhorat TH, Hammock MK, Davis DA, Fenstermacher JD. Choroid plexus papilloma. I. Proof of cerebrospinal fluid overproduction. Childs Brain. 1976;2:273-89. Medline:1022421

7 Buxton N, Punt J. Choroid plexus papilloma producing symptoms by secretion of cerebrospinal fluid. Pediatr Neurosurg. 1997;27:108-11. Medline:9520084 doi:10.1007/900121236

8 Bauer DF, Tubbs RS, Acakpo-Satchivi L. Mycoplasma meningitis resulting in increased production of cerebrospinal fluid: case report and review of the literature. Childs Nerv Syst. 2008;24:859-62. Medline:18305943 doi:10.1007/s00381-008-0590-z

9 Casey KF, Vries JK. Cerebral fluid overproduction in the absence of tumor or villous hypertrophy of the choroid plexus. Childs Nerv Syst. 1989;5:332-4. Medline:2805006 doi:10.1007/BF00274525

10 Britz GW, Kim DK, Loeser JD. Hydrocephalus secondary to diffuse villous hyperplasia of the choroid plexus. Case report and review of the literature. J Neurosurg. 1996;85:689-91. Medline:8814177 doi:10.3171/jns.1996.85.4.0689

11 Rekate HL, Erood S, Brodky JA, Chizeck HJ, Spear T, Ko W, et al. Etiology of ventriculomegaly in choroid plexus papilloma. Pediatr Neurosci. 1985-1986;12:196-201. Medline:3843618 doi:10.1159/000102050

12 Rekate HL. A consensus on the classification of hydrocephalus: its utility in the assessment of abnormalities of cerebrospinal fluid dynamics. Childs Nerv Syst. 2011;27:1535-41. Medline:21928019 doi:10.1007/s00381-011-1558-y

13 Collmann H, Sörensen N, Krauss J. Hydrocephalus in craniocystostomy: a review. Childs Nerv Syst. 2005;21:902-12. Medline:15866600 doi:10.1007/s00381-004-1116-y

14 Tamburri G, Caldarrelli M, Massimi L, Gasparini G, Pelo S, Di Rocco C. Complex craniocystostomies: a review of the prominent clinical features and the related management strategies. Childs Nerv Syst. 2012;28:1511-23. Medline:22872268 doi:10.1007/s00381-012-1819-4

15 Zhu X, Di Rocco C. Choroid plexus coagulation for hydrocephalus not due to CSF overproduction: a review. Childs Nerv Syst. 2013;29:35-42. Medline:23151740 doi:10.1007/s00381-012-1960-0

16 Davson H, Segal MB. The effects of some inhibitors and accelerators of sodium transport on the turnover of 22Na in the cerebrospinal fluid and the brain. J Physiol. 1970;209:131-53. Medline:5499038

17 Husted RF, Reed DJ. Regulation of cerebrospinal fluid potassium by the cat choroid plexus. J Physiol. 1976;259:213-21. Medline:957213

18 Husted RF, Reed DJ. Regulation of cerebrospinal fluid bicarbonate by the cat choroid plexus. J Physiol. 1977;267:411-28. Medline:17733

19 Murphy VA, Smith QR, Rapoport SI. Homeostasis of brain and cerebrospinal fluid calcium concentrations during chronic hypo- and hypercalcemia. J Neurochem. 1986;47:1735-41. Medline:3772375 doi:10.1111/j.1471-4159.1986.tb13082.x

20 Rediciz ZB, Segal MB. The structure of the choroid plexus and the physiology of the choroid plexus epithelium. Adv Drug Deliv Rev. 2004;56:1695-716. Medline:15381330 doi:10.1016/j.addr.2004.07.005

21 Brown PD, Davies SL, Speake T, Millar ID. Molecular mechanisms of cerebrospinal fluid production. Neuroscience. 2004;129:957-70. Medline:15561411 doi:10.1016/j.neuroscience.2004.07.003

22 Millar ID, Bruce JE, Brown PD. Ion channel diversity, channel expression and function in the choroid plexuses. Cerebrospinal Fluid Res. 2007;4:8. Medline:17883837 doi:10.1186/1743-8454-4-8

23 Zlokovic BV, Mackic JB, Wang L, McComb JG, McDonough A. Differential expression of Na,K-ATPase alpha and beta subunit isoforms at the blood-brain barrier and the choroid plexus. J Biol Chem. 1993;268:8019-25. Medline:8385133

24 Wu Q, Delpire E, Hebert SC, Strange K. Functional demonstration of Na+–K+–2Cl− cotransporter activity in isolated, polarized choroid plexus cells. Am J Physiol. 1998;275:C1565-72. Medline:9843718

25 Husted RF, Reed DJ. Regulation of cerebrospinal fluid bicarbonate by the cat choroid plexus. J Biol Chem. 1973;248:1919-4

26 Pearson MM, Lu J, Mount DB, Delpire E. Localization of the K(+)–Cl(−) cotransporter, KCC3, in the central and peripheral nervous systems: expression in the choroid plexus, large neurons and white matter tracts. Neuroscience. 2001;103:481-91. Medline:11246162 doi:10.1016/S0096-3007(00)00657-4

27 Johanson CE, Sweeney SM, Parmelee JT, Epstein MH. Cotransport of sodium and chloride by the adult mammalian choroid plexus. Am J Physiol. 1990;258:C1161-9. Medline:2137674

28 Praetorius J, Nejsum LN, Nielsen SA. SCL4A10 gene product maps selectively to the basolateral membrane of choroid plexus
epithelial cells. Am J Physiol Cell Physiol. 2004;286:C601-10. 
Medline:14592810
29 Fukuda H, Hirata T, Nakamura N, Kato A, Kawahara K, Wakabayashi S, et al. Identification and properties of a novel variant of NBC4 (Na+/HCO3- co-transporter 4) that is predominantly expressed in the choroid plexus. Biochim J. 2013;450:179-87. 
Medline:23205667 doi:10.1042/BI20112151
30 Nielsen S, Smith BL, Christensen EI, Agre P. Distribution of the aquaporin CHIP in secretory and resorptive epithelia and capillary endothelia. Proc Natl Acad Sci U S A. 1993;90:7275-9. 
Medline:8346245 doi:10.1073/pnas.90.15.7275
31 Boassa D, Stamer WD, Yool AJ. Ion channel function of aquaporin-1
40 Filippidis AS, Kalani MY, Rekate HL. Hydrocephalus and aquaporins: lessons learned from the bench. Childs Nerv Syst. 2011;27:27-33. 
Medline:20625739 doi:10.1007/s00381-010-1227-6
41 Mobasher A, Marples D. Expression of the AQP-1 water channel in normal human tissues: a semiquantitative study using tissue microarray technology. Am J Physiol Cell Physiol. 2004;286:C529-37. 
Medline:14592814
42 Oshio K, Song Y, Verkman AS, Manley GT. Aquaporin-1 deletion reduces osmotic water permeability and cerebrospinal fluid production. Acta Neurochir Suppl. 2003;86:525-8. 
Medline:14753499
43 Oshio K, Watanabe H, Song Y, Verkman AS, Manley GT. Reduced cerebrospinal fluid production and intracranial pressure in mice lacking choroid plexus water channel aquaporin-1. FASEB J. 2005;19:76-8. 
Medline:15533949
44 Kalani MY, Filippidis AS, Rekate HL. Hydrocephalus and aquaporins: the role of aquaporin-1. Acta Neurochir Suppl. 2012;113:51-4. 
Medline:22116423 doi:10.1007/978-3-7091-0923-6_11
45 Smith ZA, Moffakhari P, Malkadian S, Xiong Z, Vinters HV, Lazareff JA. Choroid plexus hyperplasia: surgical treatment and immunohistochemical results. Case report. J Neurosurg. 2007;107(3 Suppl):255-62. 
Medline:17918538
46 Longatti P, Basaldella L, Orvieto E, Dei Tos A, Martinuzzi A. Aquaporin(s) expression in choroid plexus tumours. Pediatr Neurosurg. 2006;42:228-33. 
Medline:16714863 doi:10.1159/000092359
47 Papadopoulos MC, Manley GT, Krishna S, Verkman AS. Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema. FASEB J. 2004;18:1291-3. 
Medline:15208268
48 Verkman AS, Binder DK, Bloch O, Auguste K, Papadopoulos MC. Three distinct roles of aquaporin-4 in brain function revealed by knockout mice. Biochem Biophys Acta. 2006;1758:1085-93. 
Medline:16564496 doi:10.1016/j.bbamem.2006.02.018
49 Castaneya-Ruiz L, González-Marrero I, González-Toledo JM, Castaneya-Ruiz A, de Paz-Carmona H, Castaleya-Perdomo A, et al. Aquaporin-4 expression in the cerebrospinal fluid in congenital human hydrocephalus. Fluids Barriers CNS. 2013;10:18. 
Medline:23659378 doi:10.1186/2045-8118-10-18
50 Igarashi H, Tsujita M, Kwee TM, Nakada T. Water influx into cerebrospinal fluid is primarily controlled by aquaporin-4, not by aquaporin-1: 17O JJVCPMI study in knockout mice. Neuroreport. 2014;25:39-43. 
Medline:24231830
51 Ooi S, Di Rocco C. Proposal of ‘evolution theory in cerebrospinal fluid dynamics and minor pathway hydrocephalus in developing immature brain. Childs Nerv Syst. 2006;22:662-9. 
Medline:16685545 doi:10.1007/s00381-005-0200-4
52 Oreskovic D, Klarica M. The formation of cerebrospinal fluid: nearly a hundred years of interpretations and misinterpretations. Brain Res Rev. 2010;64:241-62. 
Medline:20435061 doi:10.1016/j.brainresrev.2010.04.006
53 Bulat M, Klarica M. Recent insights into a new hydrodynamics
of the cerebrospinal fluid. Brain Res Rev. 2011;65:99-112.
doi:10.1016/j.brainresrev.2010.08.002
54 Lindvall-Axelsson M, Hedner P, Owman C. Corticosteroid action
on choroid plexus: reduction in Na+/K+-ATPase activity, choline
transport capacity, and rate of CSF formation. Exp Brain Res.
1987;77:605-10. Medline:2553468 doi:10.1007/BF00249613
55 Mann JD, Cookson SL, Mann ES. Differential effects of
pentobarbital, ketamine hydrochloride, and enflurane anesthesia
on CSF formation rate and outflow resistance in the rat. In:
Shulman K, Marmarou A, Miller JD, Becker DP, Hochwald GM, Brock
M, editors. Intracranial pressure IV. Berlin Heidelberg: Springer;
1980. p. 466-71.
56 Maktabi MA, Elbokl FF, Faraci FM, Todd MM. Halothane decreases
the rate of production of cerebrospinal fluid. Possible role
of vasopressin V1 receptors. Anesthesiology. 1993;78:72-82.
doi:10.1097/00000542-199301000-00012
57 Antru AA. Dose-related changes in the rate of cerebrospinal
fluid formation and resistance to reabsorption of cerebrospinal
fluid following administration of thiopental, midazolam, and etomidate in dogs. Anesthesiology. 1988;69:541-6.
Medline:3177913 doi:10.1097/00000542-198810000-00014
58 Knüttgen D, Doehn M, eymer D, Müller MR. Fentanyl-induced
increase in intracranial pressure. Anaesthesist. 1989;38:73.
Medline:2929968
59 Weininstab C, Mayer N, Richling B, Czech T, Spiss CK. Effect of
sufentanil on intracranial pressure in neurosurgical patients.
Anaesthesia. 1991;46:837. Medline:1683180 doi:10.1111/j.1365-
2044.1991.tb09596.x
60 Benthuysen JL, Kien ND, Quam DD. Intracranial pressure increases
during alfentanil-induced rigidity. Anesthesiology. 1988;68:438-40.
Medline:3125768 doi:10.1097/00000542-198803000-00021
61 Antru AA. Effect of halothane and fentanyl on the rate of CSF
production in dogs. Anesth Analg. 1983;62:581. Medline:6846881
doi:10.1213/00000539-198306000-00008
62 Antru AA. Dose-related changes in the rate of CSF formation
and resistance to reabsorption of CSF during administration of
fentanyl, sufentanil, or alfentanil in dogs. J Neurosurg Anesthesiol.
1991;3:283-90. Medline:15815425 doi:10.1097/00008506-
199112000-00008
63 Antru AA, Katz RA. Cerebral blood volume and CSF pressure
following administration of ketamine in dogs; modification by
pre- or posttreatment with hypocapnia or diazepam. J Neurosurg Anesthesiol. 1989;1:8-15. Medline:15815233
doi:10.1097/00000856-198903000-00003
64 Antru AA, Nugent M, Michenfelder JD. Enflurane causes a
prolonged and reversible increase in the rate of CSF production
in the dog. Anesthesiology. 1982;57:255-60. Medline:7125260
doi:10.1097/00000542-198210000-00001
65 Antru AA. Effects of enflurane and isoflurane on resistance to
reabsorption of cerebrospinal fluid in dogs. Anesthesiology.
1984;61:529-33. Medline:6496990 doi:10.1097/00000542-
198411000-00009
66 Han ME, Kim HJ, Lee YS, Kim DH, Choi JT, Pan CS, et al. Regulation
of cerebrospinal fluid production by caffeine consumption. BMC
Neurosci. 2009;10:110. Medline:19725982 doi:10.1186/1471-2202-
10-110
67 Faraci FM, Mayhan WG, Heistad DD. Vascular effects of
acetazolamide on the choroid plexus. J Pharmacol Exp Ther.
1990;254:23-7. Medline:2114478
68 Lorenzo AV, Hornig G, Zavaleta LM, Boss V, Welch K. Furosemide
lowers intracranial pressure by inhibiting CSF production. Z
Kinderchir. 1986;41 Suppl:10:6-2. Medline:3811613
69 Javaheiri S, Wagner KR. Butametamide decreases canine cerebrospinal
fluid production. In vivo evidence for NaCl cotransport in
the central nervous system. J Clin Invest. 1993;92:2257-61.
Medline:8227343 doi:10.1172/JCI16829
70 Migliati E, Meurice N, DuBois P, Fang JS, Somasekharan S,
Beckett E, et al. Inhibition of aquaporin-1 and aquaporin-4 water
permeability by a derivative of the loop diuretic bumetanide
acting at an internal pore-occluding binding site. Mol Pharmacol.
2009;76:105-12. Medline:19403703 doi:10.1124/mol.108.053744
71 Yool AJ, Brown EA, Flynn GA. Roles for novel pharmacological
blockers of aquaporins in the treatment of brain oedema
and cancer. Clin Exp Pharmacol Physiol. 2010;37:403-9.
Medline:19566827 doi:10.1111/j.1440-1681.2009.05244.x
72 Owler BK, Pitham T, Wang D. Aquaporins: relevance to
cerebrospinal fluid physiology and therapeutic potential in
hydrocephalus. Cerebrospinal Fluid Res. 2010;7:15.
Medline:20860832
73 Ameli PA, Madan M, Chigurupati S, Yu A, Chan SL, Pattisapu
JV. Effect of acetazolamide on aquaporin-1 and fluid flow in
cultured choroid plexus. Acta Neurochir Suppl. 2012;113:59-64.
Medline:22116425 doi:10.1007/978-3-7091-0923-6_13
74 Zhang J, An Y, Gao J, Han J, Pan X, Pan Y, et al. Aquaporin-1
translocation and degradation mediates the water transportation
mechanism of acetazolamide. PLoS ONE. 2012;7:e45976.
Medline:23029347 doi:10.1371/journal.pone.0045976
75 Tanimura Y, Hirono Y, Fujiyoshi Y. Acetazolamide reversibly inhibits
water conduction by aquaporin-4. J Struct Biol. 2009;166:16-21.
Medline:19114109 doi:10.1016/j.jsb.2008.11.010
76 Faraci FM, Mayhan WG, Heistad DD. Effect of vasopressin on
production of cerebrospinal fluid: possible role of vasopressin V1
receptors. Am J Physiol. 1990;258:R94-8. Medline:2137302
77 Segal MB, Chodobski A, Smydynger-Chodobiska J, Cammish H.
Effect of arginine vasopressin on blood vessels of the perfused
choroid plexus of the sheep. Prog Brain Res. 1992;91:451-3.
Medline:8227343 doi:10.1172/JCI16829
78 Phillips AB, Earnshaw JP, Kelly J, Paxinos G, Gritzka Z,
Menendez FAO, et al. Localization of vasopressin binding sites
in rat brain by in vitro autoradiography using a radioiodinated
V1 receptor antagonist. Neuroscience. 1988;27:749-61. Medline:3252172 doi:10.1016/0306-4522(88)90180-7

79 Ostrowski NL, Lolait SJ, Bradley DJ, O’Carroll AM, Brownstein MJ, Young WS III. Distribution of V1a and V2 vasopressin receptor messenger ribonucleic acids in rat liver, kidney, pituitary and brain. Endocrinology. 1992;131:333-5. Medline:1535312

80 Zemo DA, McCabe JT. Salt-loading increases vasopressin and vasopressin 1b receptor mRNA in the hypothalamus and choroid plexus. Neuropeptides. 2001;35:181-8. Medline:11884209 doi:10.1054/npep.2001.0864

81 Banks WA, Kastin AJ, Horvath A, Michals EA. Carrier-mediated transport of vasopressin across the blood-brain barrier of the mouse. J Neurosci Res. 1987;18:326-32. Medline:3694715 doi:10.1002/jnr.490180209

82 Tanabe S, Shimohigashi Y, Nakayama Y, Makino T, Fujita T, Nose T, et al. In vivo and in vitro evidence of blood-brain barrier transport of a novel cationic arginine-vasopressin fragment 4-9 analog. J Pharmacol Exp Ther. 1999;290:561-8. Medline:10411563

83 Brownfield MS, Kozlowski GP. The hypothalamo-choroidal tract. I. Immunohistochemical demonstration of neurophysin pathways to telencephalic choroid plexuses and cerebrospinal fluid. Cell Tissue Res. 1977;178:111-27. Medline:319910

84 Rudman D, Chawla RK. Antidiuretic peptide in mammalian choroid plexus. Am J Physiol. 1976;230:50-5. Medline:814822

85 Chodobski A, Loh YP, Corsetti S, Szymynger-Chodobska J, Johanson CE, Lim Y-P, et al. The presence of arginine vasopressin and its mRNA in rat choroid plexus epithelium. Brain Res Mol Brain Res. 1997;48:67-72. Medline:9379851

86 Chodobski A, Szymynger-Chodobska J, Johanson CE. Vasopressin mediates the inhibitory effect of central angiotensin II on cerebrospinal fluid formation. Eur J Pharmacol. 1998;347:205-9. Medline:9653883 doi:10.1016/S0014-2999(98)00225-5

87 Lindvall M, Alumets J, Edvinsson L, Fahrenkrug J, Hakanson R, Hanko J, et al. Peptidergic (VIP) nerves in the mammalian choroid plexus. Neurosci Lett. 1978;9:77-82. Medline:19605197 doi:10.1016/0304-3940(78)90051-4

88 O’Brien A, Clapp L, Singer M. Terlipressin for norepinephrine-resistant septic shock. Lancet. 2002;359:1209-10. Medline:11955542 doi:10.1016/S0140-6736(02)08225-9

89 Uriz J, Ginés P, Cárdenas A, Sort P, Jiménez W, Salmerón J, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol. 2000;33:43-8. Medline:10905583 doi:10.1016/S0168-8278(00)00158-0

90 Ioannou G, Doust J, Rockey D. Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst Rev. 2003;(1):CD002147. Medline:12535432